TriSalus Life Sciences, Inc. (NASDAQ:TLSIW) Short Interest Down 96.6% in September

TriSalus Life Sciences, Inc. (NASDAQ:TLSIW) saw a large decline in short interest in the month of September. As of September 30th, there was short interest totaling 100 shares, a decline of 96.6% from the September 15th total of 2,900 shares. Based on an average trading volume of 11,600 shares, the days-to-cover ratio is currently 0.0 days. Based on an average trading volume of 11,600 shares, the days-to-cover ratio is currently 0.0 days.

TriSalus Life Sciences Stock Performance

Shares of TLSIW stock opened at $1.34 on Friday. TriSalus Life Sciences has a 1 year low of $0.42 and a 1 year high of $5.00. The stock has a fifty day moving average of $1.65 and a two-hundred day moving average of $1.57.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.